In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
The Food and Drug Administration granted accelerated approval for Eisai and Biogen s experimental Alzheimer s drug, lecanemab, on Friday, offering a new treatment option for the more than 6.5 million people with Alzheimer s disease in the United States.
Finding a cure for Alzheimer’s disease, the most common form of dementia, is the Holy Grail of medical research. The incurable malady is — along with other dementias — the
/PRNewswire/ AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for.
An experimental Alzheimer s drug failed to slow cognitive decline in a long-awaited trial, marking the latest disappointment in a research field that has been wrought with setbacks.